Stocks & Investing
Wed, December 13, 2023
[ 12:00 AM ] - WOPRAI
Thu, October 19, 2023
[ 12:00 AM ] - WOPRAI
Mon, April 10, 2023
[ 12:00 AM ] - WOPRAI
Thu, August 4, 2022
[ 12:00 AM ] - WOPRAI
Fri, July 29, 2022
[ 12:00 AM ] - WOPRAI
Fri, June 24, 2022
[ 12:00 AM ] - WOPRAI
Fri, April 1, 2022
[ 12:00 AM ] - WOPRAI
Wed, February 23, 2022
[ 12:00 AM ] - WOPRAI
Tue, February 8, 2022
[ 12:00 AM ] - WOPRAI
Wed, January 19, 2022
[ 12:00 AM ] - WOPRAI
Mon, March 1, 2021
[ 12:00 AM ] - WOPRAI
Tue, December 15, 2020
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Thu, August 20, 2020
[ 12:00 AM ] - WOPRAI
Fri, February 7, 2020 Lawrence Biegelsen Maintained (ABT) at Buy with Increased Target to $121 on, Dec 13th, 2023
Lawrence Biegelsen of Wells Fargo, Maintained "Abbott Laboratories" (ABT) at Buy with Increased Target from $116 to $121 on, Dec 13th, 2023.
Lawrence has made no other calls on ABT in the last 4 months.
There are 4 other peers that have a rating on ABT. Out of the 4 peers that are also analyzing ABT, 1 agrees with Lawrence's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- David Lewis of "Morgan Stanley" Maintained at Hold with Decreased Target to $107 on, Thursday, October 19th, 2023
These are the ratings of the 3 analyists that currently disagree with Lawrence
- Joanne Wuensch of "Citigroup" Maintained at Strong Buy with Increased Target to $123 on, Monday, December 11th, 2023
- Matt Miksic of "Barclays" Maintained at Buy with Increased Target to $133 on, Thursday, October 19th, 2023
- Jayson Bedford of "Raymond James" Maintained at Buy with Decreased Target to $110 on, Thursday, October 19th, 2023
